1. Home
  2. TSHA vs WEN Comparison

TSHA vs WEN Comparison

Compare TSHA & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.02

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Wendy's Company (The)

WEN

Wendy's Company (The)

HOLD

Current Price

$9.04

Market Cap

1.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSHA
WEN
Founded
2019
1969
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
TSHA
WEN
Price
$6.02
$9.04
Analyst Decision
Strong Buy
Hold
Analyst Count
8
22
Target Price
$11.63
$8.84
AVG Volume (30 Days)
2.6M
9.7M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
8.28%
EPS Growth
5.56
N/A
EPS
N/A
0.29
Revenue
$9,773,000.00
$2,176,891,000.00
Revenue This Year
N/A
$2.26
Revenue Next Year
$1,152.42
$0.94
P/E Ratio
N/A
$30.36
Revenue Growth
17.28
N/A
52 Week Low
$2.72
$6.07
52 Week High
$7.30
$10.62

Technical Indicators

Market Signals
Indicator
TSHA
WEN
Relative Strength Index (RSI) 48.49 64.30
Support Level $5.28 $7.84
Resistance Level $6.88 $9.45
Average True Range (ATR) 0.34 0.41
MACD -0.01 0.12
Stochastic Oscillator 31.82 98.98

Price Performance

Historical Comparison
TSHA
WEN

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

About WEN Wendy's Company (The)

The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.

Share on Social Networks: